NM_005609.4:c.645G>A
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_ModerateBP6BP7BS1BS2
The NM_005609.4(PYGM):c.645G>A(p.Lys215Lys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00838 in 1,614,182 control chromosomes in the GnomAD database, including 73 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005609.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PYGM | ENST00000164139.4 | c.645G>A | p.Lys215Lys | synonymous_variant | Exon 5 of 20 | 1 | NM_005609.4 | ENSP00000164139.3 | ||
PYGM | ENST00000377432.7 | c.381G>A | p.Lys127Lys | synonymous_variant | Exon 3 of 18 | 2 | ENSP00000366650.3 |
Frequencies
GnomAD3 genomes AF: 0.00520 AC: 792AN: 152216Hom.: 4 Cov.: 33
GnomAD3 exomes AF: 0.00458 AC: 1151AN: 251188Hom.: 3 AF XY: 0.00461 AC XY: 626AN XY: 135824
GnomAD4 exome AF: 0.00872 AC: 12741AN: 1461848Hom.: 69 Cov.: 39 AF XY: 0.00864 AC XY: 6283AN XY: 727224
GnomAD4 genome AF: 0.00519 AC: 791AN: 152334Hom.: 4 Cov.: 33 AF XY: 0.00470 AC XY: 350AN XY: 74502
ClinVar
Submissions by phenotype
Glycogen storage disease, type V Uncertain:5Benign:1Other:1
- -
- -
- -
- -
- -
- -
- -
not specified Benign:3
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Variant summary: PYGM c.645G>A alters a non-conserved nucleotide resulting in a synonymous change. Consensus agreement among computational tools predict no significant impact on normal splicing, with 3/4 computational tools predicting the variant abolishes a cryptic exonic 5' donor site. Experimental evidence suggests that this variant may affect mRNA splicing as transcripts from peripheral blood mononuclear cells showed the inclusion of intron 6 and an altered reading frame (Garcia-Consuegra_2016). In muscle tissue, the normal transcript can be identified, although with an expression of only 5% relative to controls, suggesting a "leaky" splice effect (Garcia-Consuegra_2009). However, in both studies splicing was examined in samples from compound heterozygous patients with Glycogen Storage Disease Type V and to our knowledge, the variant effect on splicing has yet to be investigated in isolation in a controlled experimental system. The variant allele was found at a frequency of 0.0084 in 1614182 control chromosomes, including 73 homozygotes, in the gnomAD database, predominantly at a frequency of 0.01 within the Non-Finnish European subpopulation. The observed variant frequency within Non-Finnish European control individuals is approximately 3-fold of the estimated maximal expected allele frequency for a pathogenic variant in PYGM causing Glycogen Storage Disease, Type V (0.0035), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. Nevertheless, c.645G>A has been reported in the literature in compound heterozygous individuals affected with Glycogen Storage Disease, Type V (Garcia-Consuegra_2009, Lucia_2012). The following publications have been ascertained in the context of this evaluation (PMID: 22250184, 34426522, 26913921, 19251976). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments. Four submitters have classified the variant as benign/likely benign, three classified it as VUS and one as pathogenic. Based on the evidence outlined above, the variant was classified as likely benign. -
not provided Uncertain:1Benign:1
PYGM: BP4, BS1, BS2 -
BS1, BP4 -
Inborn genetic diseases Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at